Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Wolfgruber, S; Salmanton-García, J; Kuate, MPN; Hoenigl, M; Brunelli, JGP.
Antifungal pipeline: New tools for the treatment of mycoses.
Rev Iberoam Micol. 2025; Doi: 10.1016/j.riam.2024.11.001
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz
Hönigl Martin
Wolfgruber Stella
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Fungal infections are becoming an escalating public health challenge, particularly among immunocompromised individuals. The partially limited efficacy of current antifungal treatments, their potential adverse effects, and the increasing problem of resistance emphasize the need for new treatment options. Existing antifungal classes-allylamines, azoles, echinocandins, polyenes, and pyrimidine analogs-face challenges due to their similarity with human cells and rising resistance. New antifungal agents, such as ibrexafungerp, rezafungin, oteseconazole, and miltefosine, offer novel mechanisms of action along with reduced toxicity. While antifungal resistance is a growing global concern, fungal infections in low- and middle-income countries (LMICs) present specific challenges with high rates of opportunistic infections like cryptococcosis and endemic mycoses such as histoplasmosis. The World Health Organization's fungal priority pathogens list highlights the prevalence of these infections in LMICs, where limited access to antifungal drugs and misuse are common. This review provides a comprehensive overview of these new agents and their mechanisms, and explores the challenges and roles of antifungal drugs in LMICs, where the burden of fungal infections is high. Continued research and development are essential to address the rising incidence and resistance of fungal infections globally.

Find related publications in this database (Keywords)
Novel antifungals
Ibrexafungerp
Rezafungin
Miltefosine
Opelconazole
Olorofim
Fosmanogepix
MAT2203
ATI2307
GR2397
NP339
LMIC
© Med Uni Graz • Imprint